- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01358214
Quality of Life After Tension Free Transvaginal Sling / Tape Operation With a Titanized Surgical Tape (TiLOOP® Tape)
Single-center, Non-randomized, Comparative, Post-marketing Surveillance Cohort Study on Validation of a Questionnaire on Quality of Life After Surgical Stabilization of the Urethra With Titanized Polypropylene Mesh (TiLOOP® Tape)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The prevalence of urinary incontinence in the adult female population has been estimated between 10% and 40%. Several treatment alternatives have been suggested until now. Nevertheless, the ideal treatment has not been identified yet. On the one hand this is related to the low amount of valid scientific information regarding different treatment methods. On the other hand the impact of patients' quality of life, which plays a major role, has not been fully considered. To date, there is no established Questionnaire on Quality of Life that provides physicians an assistance to obtain information on the subjective effects caused by stress urinary incontinence.
In the present study the patients' Quality of Life will be assessed by use of two questionnaires, that is a new one and an already validated questionnaire. The study population consists of patients who already received an implantation of a sub-urethral surgical mesh (TiLOOP® Tape), of symptomatic patients before an operation, and of a group of non-symptomatic women. Subjects will be asked in a single visit only to fill in both questionnaires.
Furthermore the safety and effectiveness of the TiLOOP® Tape mesh will be evaluated in the study arm of treated patients.
Study has been terminated after major recruitment failure (only 21 instead of 240 patients has been included).
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Berlin, Germany, 10787
- Franziskus-Krankenhaus Berlin Akademisches Lehrkrankenhaus der Charité - Universtätsmedizin Berlin
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
The indicated or treated population of women showing stress urinary incontinence that should / has been treated with a surgical mesh.
The sample of patients treated with TiLOOP® Tape at the single center between 2007 and 2009 represents the patient population for which the medical device is intended. The clinic continues to examine women with incontinence symptoms requiring a mesh implant. This group of patients is assumed to be similar to the study arm of treated patients.
The Non-symptomatic Population consists of women comparable in age but without urinary incontinence
Description
Inclusion Criteria:
- Depending on study arm:
- Women with a TiLOOP® Tape implant, Implanted between 2007 and 2009 at the study center - OR -
- Woman with a planned Tape implantation at the study center - OR -
- Woman with no disease related to incontinence
- Subject is able to understand the nature, relevance and significance of the clinical trial
- Subject has given informed consent
Exclusion Criteria:
- Subject revoked consent
- Lack of subject's compliance regarding data collection or examination in the scope of the trial (Non-Compliance)
- Subject institutionalized by court or official order (MPG §20.3)
- Subject participates in another clinical investigation
Study Plan
How is the study designed?
Design Details
- Observational Models: Case-Control
- Time Perspectives: Cross-Sectional
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Patients treated with a surgical mesh
This arm of study patients is defined by patients treated with a TiLOOP® Tape mesh between 2007 and 2009 at the Franziskus Krankenhaus, Berlin.
The sample of the treated population represents the patient population for which the medical device is intended.
To minimize selection bias without compromising patients' rights and welfare, all treated patients will be invited.
These patients will be asked to participate in the validation of the questionnaire on quality of life.
In addition to this safety and effectiveness of the surgical mesh implantation will be collected
|
The impact of a disease on patient's Quality of Life has meanwhile gained more influences on the choice of treatment alternatives.
The benefit of a method is currently not only defined by the objective outcome but also influenced by the Quality of Life.
Two questionnaires with 20 respectively 40 Questions should be filled in by the patients.
Other Names:
|
Intended to be treated with a mesh
This arm of the study populations is defined by patients in whom a clinical anamnesis independent of the requirements of this study suggests that a sub-urethral sling operation is indicated.
These patients will be asked to participate in the validation of the questionnaire on quality of life.
|
The impact of a disease on patient's Quality of Life has meanwhile gained more influences on the choice of treatment alternatives.
The benefit of a method is currently not only defined by the objective outcome but also influenced by the Quality of Life.
Two questionnaires with 20 respectively 40 Questions should be filled in by the patients.
Other Names:
|
Non-symptomatic Population
This arm of the study population is defined by women that show no symptoms of incontinence.
They will be asked to participate in the validation of the questionnaire on quality of life.
|
The impact of a disease on patient's Quality of Life has meanwhile gained more influences on the choice of treatment alternatives.
The benefit of a method is currently not only defined by the objective outcome but also influenced by the Quality of Life.
Two questionnaires with 20 respectively 40 Questions should be filled in by the patients.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Validation of a new questionnaire on quality of life
Time Frame: before treatment (baseline) or 6 to 24 months after treatment, respectively
|
It is expected that the newly developed questionnaire on quality of life (QoL) is equal or better in description of the impact on QoL regarding the differentiation of the study populations, as compared to the standard questionnaire.
|
before treatment (baseline) or 6 to 24 months after treatment, respectively
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety of surgical mesh implantation for treatment of urinary incontinence
Time Frame: 6-24 months after treatment
|
In the study arm of treated patients the study outcome will describe all safety relevant events occurred within the period from implantation until scheduled study examination.
The time between scheduled examination and implantation varies as the implantation it not part of this study.
The findings will therefore be stratified by 6 months, 12 months and 24 months after implantation.
|
6-24 months after treatment
|
Effectiveness of surgical mesh implantation for treatment of urinary incontinence
Time Frame: 6-24 months after treatment
|
In the study arm of treated patients, the study outcome will describe the efficacy of the TiLOOP® Tape implantation based on successful implantation and complications observed during the period from implantation until discharge from the hospital.
The time between scheduled examination and implantation varies as the implantation it not part of this study.
The findings will therefore be stratified by 6 months, 12 months and 24 months after implantation.
|
6-24 months after treatment
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Manfred Beer, Prof. MD, Franziskus-Krankenhaus Berlin Akademisches Lehrkrankenhaus der Charité - Universtätsmedizin Berlin
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- pfm 10k003 TiLOOP® Tape
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Urinary Incontinence, Stress
-
University of New MexicoRecruitingUrinary Incontinence | Urge Incontinence | Stress Incontinence, FemaleUnited States
-
Juna d.o.o.CompletedFemale Stress Urinary Incontinence | Mixed Incontinence, Urge and Stress
-
University of California, San FranciscoNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Stanford...CompletedUrinary Incontinence, Stress | Urge Incontinence | Urinary Stress Incontinence | Stress Incontinence, Urinary | Stress Incontinence | Stress Incontinence, Female | Urgency UrinaryUnited States
-
Far Eastern Memorial HospitalRecruitingWomen With Stress Urinary IncontinenceTaiwan
-
Université de SherbrookeRecruitingUrinary Incontinence | Urinary Stress Incontinence | Post-Prostatectomy Incontinence | Stress Incontinence, MaleCanada
-
Hadassah Medical OrganizationCompletedUrinary Stress Incontinence (SI)Israel
-
University Magna GraeciaUnknownStress Urinary IncontinenceItaly
-
University of California, IrvineWithdrawnStress Urinary IncontinenceUnited States
-
Eli Lilly and CompanyBoehringer IngelheimCompleted
-
Eli Lilly and CompanyBoehringer IngelheimCompletedUrinary Stress IncontinenceUnited States
Clinical Trials on Questionnaire on Quality of Life.
-
Elizabeth Van EyckenFlemish League Against CancerCompletedQuality of Life | Colorectal CancerBelgium
-
University of MessinaUniversità degli Studi di Ferrara; University of Pavia; Careggi Hospital; Fondazione...UnknownPatient-Reported Outcome Measures in Wild-Type and Variant Cardiac Transthyretin Amyloidosis (ITALY)Transthyretin AmyloidosisItaly
-
University Hospital, MontpellierPediatric and Congenital Cardiology Department of Necker-enfant malades University...CompletedQuality of Life Assessment of Children With Congenital Heart Disease Aged 5 to 7 Years (QoL-CHD-5-7)Congenital Heart DiseaseFrance
-
City of Hope Medical CenterNational Cancer Institute (NCI)Recruiting
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid Neoplasm | COVID-19 InfectionUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid Neoplasm | Neuropathy | COVID-19 InfectionUnited States
-
M.D. Anderson Cancer CenterActive, not recruitingCervical Carcinoma | Endometrial Carcinoma | Vaginal Carcinoma | Malignant Female Reproductive System Neoplasm | Vulvar CarcinomaUnited States
-
Southwest Oncology GroupNational Cancer Institute (NCI)CompletedStage IVA Colon Cancer | Stage IVA Rectal Cancer | Stage IVB Colon Cancer | Stage IVB Rectal CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedMalignant NeoplasmUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedCaregiver Burden, Quality of Life, and Symptom Distress at Different Palliative Cancer Care SettingsMetastatic Malignant Neoplasm | Advanced Malignant Neoplasm | Recurrent Malignant Neoplasm | Locally Advanced Malignant NeoplasmUnited States